Why the study?
PCSK9 inhibitors reduce LDL-C and MACE in ACS, but no study had used PROMIS to assess their impact on quality of life.
Does Evolocumab plus statin therapy improve quality of life in patients with acute coronary syndromes compared to statin-only therapy?
Does Evolocumab plus statin therapy improve quality of life in patients with acute coronary syndromes compared to statin-only therapy?
Answers are grounded in this paper and cite their sources.
Evolocumab added to statin therapy provides significant short-term (12-week) improvements in quality of life for ACS patients compared to statins alone, though the between-group difference is no longer significant at 48 weeks.
Background PCSK9 Inhibitors (PCSK9i) can reduce LDL-C levels and the risk of long-term major adverse cardiovascular events (MACE) of patients with acute coronary syndromes (ACS). The Patient-Reported Outcome Measurement Information System (PROMIS) can effectively assess the overall health of patients. To date, no study has used PROMIS to explore patients’ quality of life (QOL) of ACS patients treated with PCSK9i. Purpose To assess PCSK9i's impact on ACS patients' QOL, compare PCSK9i plus statin vs statin-only therapy using PROMIS 10, and analyze the association between PROMIS scores and MACE. Methods The EMSIACS trial is a prospective, randomized, open-label, parallel-group, multicenter study registered at ClinicalTrials.gov. This study presents exploratory outcomes from this trial. From September 2020 to March 2022, a total of 500 ACS patients were enrolled. Patients were randomly assigned in a 1:1 ratio to receive Evolocumab plus statin therapy or statin-only therapy. QOL was assessed using PROMIS 10 at baseline, week 12, and week 48. PROMIS 10 includes two summary scores: Global Physical Health (GPH, including physical health, physical function, fatigue and pain intensity) and Global Mental Health (GMH, including overall quality of life, mental health, satisfaction with social activities, and emotional problems). At week 48, MACE were evaluated in the Evolocumab group. Results At week 12, GPH and GMH scores in Evolocumab group were significant compared with baseline (P<0.05) and the changes in scores were significant compared with Statin group (P<0.05), and the improvement of pain intensity, mental health, and satisfaction with social activities of Evolocumab group were significant compared with Statin group(P<0.05). Meanwhile, Evolocumab group showed significant differences in physical health and pain intensity compared to baseline (P<0.05). No significant difference was observed for physical function and fatigue(P>0.05). GMH items were significant compared with baseline (P< 0.05). At week 48, GPH, GMH and all items of Evolocumab group significantly improvement compared with baseline (P<0.05), but there was no significant difference between Evolocumab group and Statin group (P>0.05). At week 48, emotional problems in patients with MACE in the Evolocumab group deteriorated, and the score difference was significant compared with non-MACE (P<0.05). Conclusions Short-term, PCSK9i significantly improved QOL of ACS patients in both physical and mental health, and the efficacy was better than that of statins, especially in pain intensity, mental health and satisfaction with social activities. Long-term, PCSK9i sustained QOL improvements for ACS patients. The occurrence of MACE in ACS patients treated with PCSK9i may be correlated with emotional problems.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: